X

Trial Profile

A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Pembrolizumab in HLA-A2+ Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; PVX 410 (Primary) ; Poly ICLC
Indications Advanced breast cancer; Triple negative breast cancer
Focus Pharmacodynamics

Most Recent Events

13 Nov 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
13 Nov 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
21 Dec 2022 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com